COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,441 Articles (22,835 medRxiv, 8,606 bioRxiv)

Most recent first Previous |  Page 1149: Articles 11481-11490  | Next

#COVIDisAirborne: AI-Enabled Multiscale Computational Microscopy of Delta SARS-CoV-2 in a Respiratory Aerosol
Dommer, A., Casalino, L., Kearns, F., Rosenfeld, M., Wauer, N., Ahn, S.-H., Russo, J., Oliveira, S., Morris, C., Bogetti, A., Trifan, A., Brace, A., Sztain, T., Clyde, A., Ma, H., Chennubhotla, C., Lee, H., Turilli, M., Khalid, S., Tamayo-Mendoza, T., Welborn, M., Christiansen, A., Smith, D. G. A., Qiao, Z., Sirumalla, S. K., O'Connor, M., Manby, F., Anandkumar, A., Hardy, D., Phillips, J., Stern, A., Romero, J., Clark, D., Dorrell, M., Maiden, T., Huang, L., McCalpin, J., Woods, C., Gray, A., Williams, M., Barker, B., Rajapaksha, H., Pitts, R., Gibbs, T., Stone, J., Zuckerman, D., Muholland, A., Miller, T., Jha, S., Ramanathan, A., Chong, L., Amaro, R. E.
10.1101/2021.11.12.468428 — Posted: 2021-11-15
Estimation of R0 for the spread of SARS-CoV-2 in Germany from Excess Mortality
Prada Salcedo, J. P., Maag, L. E., Siegmund, L., Bencurova, E., Chunguang, L., Koutsilieri, E., Dandekar, T., Scheller, C.
10.1101/2021.11.14.21266295 — Posted: 2021-11-15
Early and rapid identification of COVID-19 patients with neutralizing type I-interferon auto-antibodies by an easily implementable algorithm
Akbil, B., Meyer, T., Stubbemann, P., Thibeault, C., Staudacher, O., Niemeyer, D., Jansen, J., Muehlemann, B., Doehn, J.-M., Tabeling, C., Nusshag, C., Hirzel, C., Soekler Sanchez, D., Nieters, A., Lother, A., Duerschmied, D., Schallner, N., Lieberum, J. N., August, D., Rieg, S., Falcone, V., Hengel, H., Koelsch, U., Unterwalder, N., Huebner, R.-H., Jones, T. C., Suttorp, N., Drosten, C., Warnatz, K., Spinetti, T., Schefold, J. C., Doerner, T., Sander, L., Corman, V. M., Merle, U., Kurth, F., von Bernuth, H., Meisel, C., Goffinet, C.
10.1101/2021.11.12.21266249 — Posted: 2021-11-15
Seroprevalence in Tamil Nadu through India's two COVID waves: Evidence on antibody decline following infection and vaccination
Selvavinayagam, T. S., Somasundaram, A., Selvam, J. M., Ramachandran, S., P., S., V., V., C., A. B. K., Subramanian, S., Raju, S., V., P., N., Y., Subramanian, G., A., R., D.N., D., Imad, S., Tandel, V., Parasa, R., Sachdeva, S., Malani, A.
10.1101/2021.11.14.21265758 — Posted: 2021-11-15
Comparative analysis of antibody production by mRNA 1273, AZD 1222 and BBIBP-CorV on elderly people suffering from different co-morbidity in Bangladesh
hoque, a., Rahman, M., Parvez, S., Imam, H., Nahar, N., Chowdhury, F. U. H.
10.1101/2021.11.15.21266338 — Posted: 2021-11-15
Effect of COVID-19 vaccination on menstrual periods in a retrospectively recruited cohort
Male, V.
10.1101/2021.11.15.21266317 — Posted: 2021-11-15 Discussion: Offsite
Effectiveness of BNT162b2 (Comirnaty, Pfizer-BioNTech) COVID-19 booster vaccine against covid-19 related symptoms in England: test negative case-control study
Andrews, N., Stowe, J., Kirsebom, F., Gower, C., Ramsay, M., Lopez Bernal, J.
10.1101/2021.11.15.21266341 — Posted: 2021-11-15
Pulmonary thromboembolism in COVID-19 Patients on CT Pulmonary Angiography - A Single-Centre Retrospective Cohort Study in the United Arab Emirates
Saeed, G. A., Gaba, W. H., Adi, A. A. K. M., Al Marshoodi, R. O., Al Mazrouei, S. S., Shah, A. R.
10.1101/2021.11.14.21266214 — Posted: 2021-11-15
Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States
Li, R., Liu, H., Fairley, C. K., Zou, Z., Xie, L., Li, X., Shen, M., Li, Y., Zhang, L.
10.1101/2021.11.14.21266318 — Posted: 2021-11-14 Discussion: Onsite
Revisiting the estimation of Covid-19 prevalence: Implications for rapid testing
Zhou, L., Diaz-Pachon, D. A., Rao, J. S.
10.1101/2021.11.12.21266254 — Posted: 2021-11-14

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).